Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Global Health & Infection Department, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.
BMC Psychiatry. 2018 Apr 11;18(1):100. doi: 10.1186/s12888-018-1679-x.
Treatment-resistant depression (TRD) is a serious and relatively common clinical condition. Lack of consensus on defining and staging TRD remains one of the main barriers to understanding TRD and approaches to intervention. The Maudsley Staging Method (MSM) is the first multidimensional model developed to define and stage treatment-resistance in "unipolar depression". The model is being used increasingly in treatment and epidemiological studies of TRD and has the potential to support consensus. Yet, standardised methods for rating the MSM have not been described adequately. The aim of this report is to present standardised approaches for rating or completing the MSM.
Based on the initial development of the MSM and a narrative review of the literature, the developers of the MSM provide explicit guidance on how the three dimensions of the MSM--treatment failure, severity of depressive episode and duration of depressive episode-- may be rated.
The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory (MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension, severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for scoring the third dimension, duration of depressive episode.
The approaches provided should have clinical and research utility in staging TRD. However, in proposing this model, we are fully cognisant that until the pathophysiology of depression is better understood, staging methods can only be tentative approximations. Future developments should attempt to incorporate other biological/ pathophysiological dimensions for staging.
治疗抵抗性抑郁症(TRD)是一种严重且相对常见的临床情况。缺乏对 TRD 的定义和分期的共识仍然是理解 TRD 和干预方法的主要障碍之一。Maudsley 分期法(MSM)是第一个为定义和分期“单相抑郁症”中的治疗抵抗而开发的多维模型。该模型越来越多地用于 TRD 的治疗和流行病学研究,并有潜力支持共识。然而,尚未充分描述用于评定 MSM 的标准化方法。本报告的目的是提出评定或完成 MSM 的标准化方法。
基于 MSM 的最初开发和对文献的叙述性综述,MSM 的开发者提供了关于如何评定 MSM 的三个维度(治疗失败、抑郁发作严重程度和抑郁发作持续时间)的明确指导。
MSM 的核心维度,即治疗失败,可以使用 Maudsley 治疗量表(MTI)进行评估,MTI 是为完成 MSM 而开发的一种新方法。MTI 由一个相对全面的药物清单组成,提供了用于评定剂量和多次发作治疗的选项。第二个维度,症状严重程度,可以使用简单的工具进行评估,如临床总体印象、精神状态评定或标准诊断清单中的检查表。标准化还提供了用于评定第三个维度,抑郁发作持续时间的简单评分量表。
提供的方法在分期 TRD 方面具有临床和研究实用性。然而,在提出这个模型时,我们充分意识到,在更好地理解抑郁症的病理生理学之前,分期方法只能是暂定的近似值。未来的发展应尝试纳入其他生物学/病理生理学维度进行分期。